文献速递脑血管病

非维生素K拮抗剂口服抗凝药在亚洲房颤患者中的有效性与安全性

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation.
PubMed 文献 · Stroke · 2017-10-03

该研究利用韩国国民健康保险数据库,比较NOAC与华法林在高危非瓣膜性房颤患者中的有效性和安全性。结果显示NOAC组缺血性卒中风险与华法林相似,但颅内出血风险更低;达比加群和阿哌沙班还显著降低全因死亡风险。

要点

  • NOAC组缺血性卒中风险与华法林相似,颅内出血风险更低。
  • 达比加群和阿哌沙班降低全因死亡和复合终点风险,利伐沙班无显著差异。
  • 初治患者中达比加群和阿哌沙班预防颅内出血优于华法林。

核心结论

  • 在高危亚洲房颤人群中,三种NOAC缺血性卒中风险与华法林相似,颅内出血风险更低。
  • 达比加群和阿哌沙班全因死亡率显著低于华法林,利伐沙班无显著差异。

研究设计与样本

  • 基于韩国国民健康保险服务数据库的回顾性队列研究,纳入2014-2015年高危房颤患者。

主要发现

  • NOAC组缺血性卒中风险与华法林相似,颅内出血和全因死亡风险更低。
  • 三种NOAC缺血性卒中风险均与华法林相似,颅内出血风险均更低。
  • 达比加群和阿哌沙班全因死亡及复合净临床结局风险低于华法林,利伐沙班无显著差异。

临床怎么用

  • 高危亚洲房颤患者可优先考虑NOAC而非华法林以降低颅内出血风险。
  • 需降低死亡风险时可优先选择达比加群或阿哌沙班。

局限性

  • 观察性研究设计可能存在残余混杂。
  • 仅代表韩国人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: There are limited real-world data comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians with nonvalvular atrial fibrillation. We aimed to compare the effectiveness and safety between NOACs and warfarin users in the Korean atrial fibrillation population, with particular focus on high-risk patients. METHODS: Using the Korean National Health Insurance Service database, we analyzed the risk of ischemic stroke, intracranial hemorrhage (ICH) events, and all-cause death in NOAC users (n=11 611 total, n=5681 taking rivaroxaban, n=3741 taking dabigatran, and n=2189 taking apixaban) compared with propensity score-matched warfarin users (n=23 222) among patients with high-risk atrial fibrillation (CHA2DS2-VASc score ≥2) between 2014 and 2015. RESULTS: NOAC treatment was associated with similar risk of ischemic stroke and lower risk of ICH and all-cause mortality compared with warfarin. All 3 NOACs were associated with a similar risk of ischemic stroke and a lower risk of ICH compared with warfarin. Dabigatran and apixaban were associated with a lower risk of total mortality and the composite net clinical outcome (ischemic stroke, ICH, and all-cause death) compared with warfarin, whereas this was nonsignificant for rivaroxaban. Among previously oral anticoagulant-naive patients (n=23 262), dabigatran and apixaban were superior to warfarin for ICH prevention, whereas rivaroxaban and warfarin were associated with similar risk of ICH. CONCLUSIONS: In real-world practice among a high-risk Asian atrial fibrillation population, all 3 NOACs demonstrated similar risk of ischemic stroke and lower risk of ICH compared with warfarin. All-cause mortality was significantly lower only with dabigatran and apixaban.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cha MJ, Choi EK, Han KD, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke. 2017. PMID: 28974629. doi:10.1161/STROKEAHA.117.018773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。